| Safety, activity, and immune correlates of anti–PD-1 antibody in cancer SL Topalian, FS Hodi, JR Brahmer, SN Gettinger, DC Smith, ... New England Journal of Medicine 366 (26), 2443-2454, 2012 | 14382 | 2012 |
| Safety and activity of anti–PD-L1 antibody in patients with advanced cancer JR Brahmer, SS Tykodi, LQM Chow, WJ Hwu, SL Topalian, P Hwu, ... New England journal of medicine 366 (26), 2455-2465, 2012 | 9197 | 2012 |
| Immune checkpoint blockade: a common denominator approach to cancer therapy SL Topalian, CG Drake, DM Pardoll Cancer cell 27 (4), 450-461, 2015 | 4347 | 2015 |
| Cancer regression in patients after transfer of genetically engineered lymphocytes RA Morgan, ME Dudley, JR Wunderlich, MS Hughes, JC Yang, ... Science 314 (5796), 126-129, 2006 | 4232 | 2006 |
| Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes ME Dudley, JR Wunderlich, PF Robbins, JC Yang, P Hwu, ... Science 298 (5594), 850-854, 2002 | 3813 | 2002 |
| Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates JR Brahmer, CG Drake, I Wollner, JD Powderly, J Picus, WH Sharfman, ... Journal of clinical oncology 28 (19), 3167-3175, 2010 | 3701 | 2010 |
| A randomized trial of bevacizumab, an anti–vascular endothelial growth factor antibody, for metastatic renal cancer JC Yang, L Haworth, RM Sherry, P Hwu, DJ Schwartzentruber, ... New England Journal of Medicine 349 (5), 427-434, 2003 | 3624 | 2003 |
| Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. SA Rosenberg, BS Packard, PM Aebersold, D Solomon, SL Topalian, ... The New England journal of medicine 319 (25), 1676-1680, 1988 | 3233 | 1988 |
| Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab SL Topalian, M Sznol, DF McDermott, HM Kluger, RD Carvajal, ... Journal of clinical oncology 32 (10), 1020-1030, 2014 | 2777 | 2014 |
| Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy SL Topalian, JM Taube, RA Anders, DM Pardoll Nature Reviews Cancer 16 (5), 275-287, 2016 | 2741 | 2016 |
| Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti–PD-1 therapy JM Taube, A Klein, JR Brahmer, H Xu, X Pan, JH Kim, L Chen, DM Pardoll, ... Clinical cancer research 20 (19), 5064-5074, 2014 | 2628 | 2014 |
| Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape JM Taube, RA Anders, GD Young, H Xu, R Sharma, TL McMiller, S Chen, ... Science translational medicine 4 (127), 127ra37-127ra37, 2012 | 2476 | 2012 |
| Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma SA Rosenberg, JC Yang, DJ Schwartzentruber, P Hwu, FM Marincola, ... Nature medicine 4 (3), 321-327, 1998 | 2274 | 1998 |
| Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma ME Dudley, JR Wunderlich, JC Yang, RM Sherry, SL Topalian, NP Restifo, ... Journal of clinical oncology 23 (10), 2346-2357, 2005 | 2180 | 2005 |
| Neoadjuvant PD-1 blockade in resectable lung cancer PM Forde, JE Chaft, KN Smith, V Anagnostou, TR Cottrell, MD Hellmann, ... New England Journal of Medicine 378 (21), 1976-1986, 2018 | 2116 | 2018 |
| Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma GQ Phan, JC Yang, RM Sherry, P Hwu, SL Topalian, ... Proceedings of the National Academy of Sciences 100 (14), 8372-8377, 2003 | 1982 | 2003 |
| Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. JC Yang, AE Chang, AR Baker, WF Sindelar, DN Danforth, SL Topalian, ... Journal of clinical oncology 16 (1), 197-203, 1998 | 1848 | 1998 |
| Gene transfer into humans—immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction SA Rosenberg, P Aebersold, K Cornetta, A Kasid, RA Morgan, R Moen, ... New England journal of medicine 323 (9), 570-578, 1990 | 1816 | 1990 |
| Control of TH17/Treg balance by hypoxia-inducible factor 1 EV Dang, J Barbi, HY Yang, D Jinasena, H Yu, Y Zheng, Z Bordman, J Fu, ... Cell 146 (5), 772-784, 2011 | 1738 | 2011 |
| Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity SL Topalian, CG Drake, DM Pardoll Current opinion in immunology 24 (2), 207-212, 2012 | 1716 | 2012 |
